CN101283796B - Health products for osteoporosis and cardio-cerebrovascular disease using walnut oil as matrix - Google Patents
Health products for osteoporosis and cardio-cerebrovascular disease using walnut oil as matrix Download PDFInfo
- Publication number
- CN101283796B CN101283796B CN2008100583635A CN200810058363A CN101283796B CN 101283796 B CN101283796 B CN 101283796B CN 2008100583635 A CN2008100583635 A CN 2008100583635A CN 200810058363 A CN200810058363 A CN 200810058363A CN 101283796 B CN101283796 B CN 101283796B
- Authority
- CN
- China
- Prior art keywords
- walnut oil
- farnoquinone
- osteoporosis
- matrix
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention relates a preparation containing organic effective components and having curative and healthy functions on osteoporosis and cardiovascular and cerebrovascular diseases. The preparation is prepared by mixing vitamin K2 0.01 to 0.5 g with coenzyme Q10 5 to 10 g, heating with walnut oil 300 g at 40 DEG C, stirring to dissolve, adding walnut oil 599.5 to 694.99 g under stirring, and mixing uniformly to obtain a mixed solution 1000 g. The solution can be further packaged to soft capsule or hard capsule, and the vitamin K2 is one or a plurality of kinds of vitamin K2 (5) to K2 (50). The preparation can be used for prevention and assistant treatment of the cardiovascular disease, and has the healthy and the curative effects on increasing bone density and resisting osteoporosis.
Description
Technical field
The present invention relates to contain the preparation with treatment and health care of organic active ingredient.
Background technology
Osteoporosis is common disease, frequently-occurring disease; The medicine of treatment or prevention of osteoporosis has sex hormone, calcitonin, estrogenic agents and diphosphonate etc.; But these medicines all have certain side effect, as causing coronary heart disease, rhinitis, DVT and esophagus stimulation etc.In recent years research shows: one of reason of induced osteoporosis phenomenon is the deficiency owing to farnoquinone in the blood; Can not promote the generation of the solid factor protein matter C of factor III, IV, the V factor and anti-freezing, protein s; Cause the calcification protein (BGP) in the gelatine matter and organize γization protein (MGP) can't generate the bone sprout cell, thereby form osteoporosis.Farnoquinone, in generation of the bone sprout cell that promotes the formation sclerotin and the effectively breakage of inhibition osteocyte, treatment and prevention of osteoporosis disease aspect have the curative effect of uniqueness.Before this, we have proposed " a kind of synthetic method of producets in vitamin K 2 series " with application number 2007100660444, and it is with the 2-methyl isophthalic acid, and the 4-naphthoquinones and the long-chain terpenes tertiary alcohol are raw material, and with the 2-methyl isophthalic acid, the 4-naphthoquinones is through KBH
4Reduction forms quinhydrones; Again in nitromethane-n-hexane system; Make catalyst with anhydrous zinc chloride, BFEE, cuprous bromide; Under 40-43 ℃, carry out the Fridel-Crafts alkylated reaction with the long-chain terpenes tertiary alcohol, introduce the long-chain terpenyl, again with the synthetic corresponding farnoquinone of the aqueous isopropanol oxidation of ferric trichloride in the C3 position of quinhydrones.Because this invention reaction condition is gentle, yield is good, and reagent is recyclable and cost is cheap, and this invention has been applied in applicant's production.
Co-Q10 is in nineteen fifty-seven isolation identification from the cardiod plastochondria; Be the fat-soluble quinones that extensively exists in the organism, in the human body respiration chain, play an important role in proton displacement and the electronics transmission, can be used as cellular metabolism and cellular respiration activator; Or important antioxidants and nonspecific immunity strengthening agent; Have the accelerating oxidation phosphorylation reaction, protection biofilm structure integrality is having unique curative effect aspect prevention and the treatment angiocardiopathy.The human body synthesizing coenzyme Q 10 began to descend year by year after 20 years old, and the Q10 content in the middle aged human body is merely the half the of young people or still less.In edible oil, add Co-Q10 protection the elderly heart, in application for a patent for invention number 200410010326.9 " a kind of health-care edible oils that are rich in Co-Q10 ", propose.In addition, application number 00102765.4 " a kind of Coenzyme Complex Q10 nutrient and healthcare products " has been noticed Co-Q10 and the issuable effect of Combination application as the vitamin A of active oxygen radical scavenger, C, E.And walnut oil contains the unrighted acid of 80-95%, the content of omega-fatty acid, ω-6 aliphatic acid be other edible oils kind, be 3 to 4 times of common rapeseed oil content.Especially, walnut oil is rich in trace elements such as vitamin A, B1, B2, C, E and Ca, Mg, itself has the plant chemical ingredient that overcomes the Co-Q10 negative consequence.
Therefore, have different bioactive compositions with above-mentioned several kinds for human body and prepare by a certain percentage, do not propose to the health care or the therapeutic combination of senile osteoporosis and cardiovascular and cerebrovascular disease.
Summary of the invention
The object of the present invention is to provide the food or the Ricipe for health care food that common osteoporosis and cardiovascular and cerebrovascular disease are had treatment and health care.
The present invention accomplishes in the following manner:
0.01g～0.5g farnoquinone is mixed with 5g～100g Co-Q10, after 40 ℃ of heated and stirred dissolvings, add 599.5 g～694.99g walnut oil in stirring down again, mix, be made into the 1000g mixed solution with the 300g walnut oil.
That described solution can further be packaged into is soft, hard shell capsules or cellulose capsule, makes 2000 altogether, every dress 0.5g, and every farnoquinone content is 5ug～250ug, Co-Q10 content is 2.5mg～50mg.
Described farnoquinone is that farnoquinone (5) arrives one or more in the farnoquinone (50).
Above-mentioned walnut oil is for being that raw material obtains through squeezing or extraction with the walnut kernel, is rich in unrighted acid and vitamin A thereof, B1, B2, the C of 65-95%, the product of E.
The present invention has following beneficial effect:
Farnoquinone and Co-Q10 itself is human body endogenous product, and it has no side effect, and takes safety, its good curing and angiocardiopathy preventing, and experiment is confirmed by lots of clinical to increase bone density, anti-osteoporosis activity.The present invention is a matrix with the health food walnut oil that has an abundant nutrition for treatment and angiocardiopathy preventing; Utilize the applicant to produce the unique conditions of farnoquinone series of products; And in invention prescription through adding exogenous human body Co-Q10; Can make the above-mentioned substance content in the human body maintain normal level; Thereby reach prevention and supplemental treatment because the above-mentioned substance content that the growth at age causes reduces the various diseases that causes, good health care effect and certain treatment curative effect can be arranged sufferers of osteoporosis face, cardiovascular and cerebrovascular disease patient, particularly postmenopausal women, mental worker and the elderly.
Below through embodiment the present invention is further specified, but the present invention does not receive the restriction of the embodiment that lifts.
The specific embodiment
Embodiment 1: 0.4g farnoquinone (20) is mixed with the 30g Co-Q10, after 40 ℃ of heated and stirred dissolvings, add the 669.6g walnut oil in stirring down with the 300g walnut oil again, mix, be made into the 1000g mixed solution.
Embodiment 2: in clean workplace, the lucifuge operation mixes 0.01g farnoquinone (20) with the 100g Co-Q10; After 40 ℃ of heated and stirred dissolvings, add the 599.9g walnut oil in stirring down with about 300g walnut oil again, mix; Be made into the 1000g mixed solution, in the impouring hard shell capsules.Every dress 0.5g, every farnoquinone content is 5ug, and Co-Q10 content is 50mg, and packing promptly gets.
Embodiment 3: in clean workplace, the lucifuge operation mixes 0.1g farnoquinone (35) with the 40g Co-Q10; After 40 ℃ of heated and stirred dissolvings, add the 659.9g walnut oil in stirring down with about 300g walnut oil again, mix; Be made into the 1000g mixed solution, be pressed into soft capsule, every dress 0.5g; Every farnoquinone content is 250ug, and Co-Q10 content is 2.5mg, and packing promptly gets.
Embodiment 4: in clean workplace, the lucifuge operation mixes 0.3g farnoquinone (45) with the 60g Co-Q10; After 40 ℃ of heated and stirred dissolvings, add the 639.7g walnut oil in stirring down with about 300g walnut oil again, mix; Be made into the 1000g mixed solution, be pressed into soft capsule, every dress 0.5g; Every farnoquinone content is 250ug, and Co-Q10 content is 2.5mg, and packing promptly gets.
Embodiment 5: in clean workplace, the lucifuge operation mixes 0.2g farnoquinone (5) and 0.3g K2 (35) with the 5g Co-Q10; After 40 ℃ of heated and stirred dissolvings, add the 694.5g walnut oil in stirring down with about 300g walnut oil again, mix; Be made into the 1000g mixed solution, be pressed into soft capsule, every dress 0.5g; Every farnoquinone content is 250ug, and Co-Q10 content is 2.5mg, and packing promptly gets.
In the test of observation property; The capsule finished product that provides according to embodiment 2,3; Through two routine congestive heart failures, coronary heart disease, angina pectoris initial stage patient, seven routine myocardial ischemias, hyperpietic's morning and evening every day hard shell capsules, edible tri month its symptom all has stable or improves.By above dosage, two routine sufferers of osteoporosis face edible tris are after individual month, and its symptom all has improvement.
Claims (2)
1. be the treatment osteoporosis of matrix and the health products of cardiovascular and cerebrovascular diseases with the walnut oil, it is characterized in that:
0.01g～0.5g farnoquinone is mixed with 5g～100g Co-Q10, after 40 ℃ of heated and stirred dissolvings, add 599.5g～694.99g walnut oil in stirring down again, mix, be made into the 1000g mixed solution with the 300g walnut oil;
Wherein, farnoquinone is that farnoquinone (5) arrives one or more in the farnoquinone (50).
2. according to claim 1 is the treatment osteoporosis of matrix and the health products of cardiovascular and cerebrovascular diseases with the walnut oil; It is characterized in that further being packaged into soft capsule or hard shell capsules; Make 2000 altogether; Every dress 0.5g, every farnoquinone content is 5 ug～250ug, Co-Q10 content is 2.5mg～50mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100583635A CN101283796B (en) | 2008-05-08 | 2008-05-08 | Health products for osteoporosis and cardio-cerebrovascular disease using walnut oil as matrix |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100583635A CN101283796B (en) | 2008-05-08 | 2008-05-08 | Health products for osteoporosis and cardio-cerebrovascular disease using walnut oil as matrix |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101283796A CN101283796A (en) | 2008-10-15 |
| CN101283796B true CN101283796B (en) | 2012-05-30 |
Family
ID=40056375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100583635A Active CN101283796B (en) | 2008-05-08 | 2008-05-08 | Health products for osteoporosis and cardio-cerebrovascular disease using walnut oil as matrix |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101283796B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101849971A (en) * | 2010-06-08 | 2010-10-06 | 玉溪健坤生物药业有限公司 | Soft capsule containing coenzyme Q10 and preparation method and application thereof |
| EP2605663A1 (en) * | 2010-08-17 | 2013-06-26 | Chr. Hansen A/S | Lactococcus lactis strain with high vitamin k2 production |
| CN102488207A (en) * | 2011-12-14 | 2012-06-13 | 广州善元堂医药科技有限公司 | Coenzyme Q10 soft capsule and its preparation method |
| CN103142640A (en) * | 2013-04-01 | 2013-06-12 | 李拖平 | Health care product containing vitamin K2 and having functions of preventing and treating brittle-bone disease |
| CN108272835A (en) * | 2014-07-26 | 2018-07-13 | 广东医科大学 | Ubiquinone10The Ricipe for health care food and production technology of pre- preventing bone rarefaction are prepared with evening primrose oil |
| CN105902840B (en) * | 2016-04-12 | 2019-09-03 | 广东润和生物科技有限公司 | Cardiovascular disease and the drug of dementia and preparation method thereof caused by a kind of prevention and treatment Apolipoprotein E-deficient |
| CN108294308A (en) * | 2018-01-17 | 2018-07-20 | 上海茂久中医药科技有限公司 | A kind of white flower loropetalum chinense health products and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1278616C (en) * | 2004-06-08 | 2006-10-11 | 于新华 | Healthy edible oil with coenzyme Q10 |
-
2008
- 2008-05-08 CN CN2008100583635A patent/CN101283796B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1278616C (en) * | 2004-06-08 | 2006-10-11 | 于新华 | Healthy edible oil with coenzyme Q10 |
Non-Patent Citations (1)
| Title |
|---|
| 苏林.维生素E能否用于防治骨质疏松.《中华医学信息导报》.1994,第14页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101283796A (en) | 2008-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101283796B (en) | Health products for osteoporosis and cardio-cerebrovascular disease using walnut oil as matrix | |
| JPH05505935A (en) | Extended release formulation of vitamins, minerals and other beneficial supplements | |
| Glade | A 21st century evaluation of the safety of oral vitamin D | |
| CN103385493A (en) | Healthy food using Antarctic krill oil as main ingredient | |
| CN101849971A (en) | Soft capsule containing coenzyme Q10 and preparation method and application thereof | |
| CN101558843A (en) | Method for preparing a propolis, bee pollen and royal jelly nutritive mixture | |
| CN101283797B (en) | Health products for promoting the intelligence and strengthening the brain using walnut oil as matrix | |
| KR101517095B1 (en) | Periodontal diseases treatment and prevention composition using the natural extracts | |
| CN108272968A (en) | Containing ubiquinone10With the composition of wheat-germ oil the health food and drug for preparing pre- preventing bone rarefaction application | |
| CN100539999C (en) | Be used for fat-reducing, blood fat reducing, blood sugar lowering, blood pressure lowering, the osteoporotic compound preparation of control | |
| CN102068494B (en) | Health-care capsules with treatment effect on chemical liver injury and preparation method thereof | |
| US8673343B2 (en) | Preparation and administration of jojoba product for reducing weight, fat and blood lipid levels and for the prevention and treatment of cancer | |
| CN102125196A (en) | Bee product formulation | |
| CN101716180A (en) | Combined medicament for supplementing zinc and calcium and preparation method thereof | |
| TW201031343A (en) | A multivitamin/mineral formulation to combat the effects of environmental stress; improve immunity and improve energy while addressing vitamin and mineral deficiencies without the negative side effects of a mega dose nutritional supplement | |
| CN101194913A (en) | Natural seal oil compression biological preparation for treating hyperlipidemia and technique of preparing the same | |
| CN1262284C (en) | Health care product of hippophae rhamnoides oil | |
| US20180169071A1 (en) | Nutritional supplement composition | |
| US11458150B2 (en) | Methylphosphinic acid compositions and methods for reducing aging | |
| US20130022673A1 (en) | Enhancement of magnesium uptake in mammals | |
| CN101331948A (en) | Compound health products containing coenzyme Q10 and spirulina | |
| CN101108000B (en) | Addition-application method of functional properties fat planting food mixture | |
| WO2014150343A1 (en) | Soft gel encapsulation | |
| AU2004266634A1 (en) | Enhancement of magnesium uptake in mammals | |
| CN100364969C (en) | Water soluble vitamins D2 preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20081015 Assignee: Kunming Goodkwang Health-Care Food Co., Ltd. Assignor: Kunming Yunda Medicine Development Co., Ltd. Contract record no.: 2013530000020 Denomination of invention: Health products for osteoporosis and cardio-cerebrovascular disease using walnut oil as matrix Granted publication date: 20120530 License type: Exclusive License Record date: 20130321 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Kunming Goodkwang Health-Care Food Co., Ltd. Assignor: Kunming Yunda Medicine Development Co., Ltd. Contract record no.: 2013530000020 Date of cancellation: 20150408 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160616 Address after: 515000 Guangdong province Haojiang District Shantou City Binhai Industrial Park Road Huatai Office Building Room 101 Patentee after: Guangdong Gusheng Medical Technology Co., Ltd. Address before: 650032, No. 998, village head, Longquan Road, Wuhua District, Yunnan, Kunming Patentee before: Kunming Yunda Medicine Development Co., Ltd. |